Loading...
Exploring and comparing adverse events between PARP inhibitors
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a funct...
Saved in:
| Published in: | Lancet Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292736/ https://ncbi.nlm.nih.gov/pubmed/30614472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30786-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|